Exelixis, Inc. Files 8-K for Undisclosed Event
Ticker: EXEL · Form: 8-K · Filed: Oct 15, 2024 · CIK: 939767
Sentiment: neutral
Topics: 8-k, other-event
TL;DR
EXEL filed an 8-K for an 'Other Event' - details TBD.
AI Summary
On October 14, 2024, Exelixis, Inc. filed an 8-K report to disclose an "Other Event." The filing does not contain specific details about the event itself, but it indicates a material event has occurred that requires public disclosure.
Why It Matters
This filing signals a significant development for Exelixis, Inc. that warrants immediate public attention, though the specifics are not yet revealed.
Risk Assessment
Risk Level: medium — The filing indicates a material event has occurred, but the lack of specific details creates uncertainty and potential risk.
Key Numbers
- 000-30235 — SEC File Number (Identifies Exelixis's filings with the SEC.)
- 04-3257395 — IRS Employer Identification No. (Tax identification number for Exelixis.)
Key Players & Entities
- EXELIXIS, INC. (company) — Registrant
- October 14, 2024 (date) — Date of earliest event reported
- 1851 Harbor Bay Parkway Alameda, California 94502 (address) — Principal executive offices
FAQ
What is the specific nature of the "Other Event" reported by Exelixis, Inc. on October 14, 2024?
The 8-K filing does not provide specific details regarding the nature of the "Other Event."
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 14, 2024.
What is Exelixis, Inc.'s principal executive office address?
Exelixis, Inc.'s principal executive office is located at 1851 Harbor Bay Parkway Alameda, California 94502.
What is the SEC file number for Exelixis, Inc.?
The SEC file number for Exelixis, Inc. is 000-30235.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 666 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2024-10-15 08:00:17
Key Financial Figures
- $0.001 — hange on which registered Common Stock $0.001 Par Value per Share EXEL The Nasdaq Sto
Filing Documents
- exel-20241014.htm (8-K) — 23KB
- exel-20241014_g1.jpg (GRAPHIC) — 54KB
- 0000939767-24-000138.txt ( ) — 275KB
- exel-20241014.xsd (EX-101.SCH) — 2KB
- exel-20241014_lab.xml (EX-101.LAB) — 21KB
- exel-20241014_pre.xml (EX-101.PRE) — 12KB
- exel-20241014_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On October 14, 2024, Exelixis, Inc. (Exelixis) announced that it has entered into a clinical development collaboration (Collaboration) with Merck & Co., Inc., known as MSD outside of the United States and Canada (Merck), to evaluate the combination of Exelixis' investigational tyrosine kinase inhibitor (TKI) zanzalintinib with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a phase 3 pivotal trial for the treatment of patients with head and neck squamous cell carcinoma (HNSCC), and zanzalintinib with WELIREG (belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2) inhibitor, in a phase 1/2 trial and two phase 3 pivotal trials for the treatment of patients with renal cell carcinoma (RCC). Under the terms of the Collaboration, Merck will supply KEYTRUDA for the ongoing, Exelixis-sponsored phase 3 STELLAR-305 pivotal trial in previously untreated PD-L1 positive recurrent or metastatic HNSCC. In addition, Merck will sponsor a phase 1/2 trial and two phase 3 pivotal trials in RCC. Merck will fund one of these phase 3 studies, and Exelixis will co-fund the phase 1/2 trial and the other phase 3 study, as well as supply zanzalintinib and cabozantinib. Exelixis maintains all global commercial and marketing rights to zanzalintinib. This Current Report on Form 8-K contains forward-looking statements, including, without limitation, statements related to Exelixis' and Merck's obligations under the Collaboration. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation, Exelixis' and Merck's ability to effect its obligations under the Collaboration, and other factors detailed from time to time under the caption "Risk Factors" in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exel
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. E XELIXIS, I NC. October 15, 2024 /s/ J effrey J . H essekiel Date Jeffrey J. Hessekiel Executive Vice President and General Counsel